Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-20T02:06:23.862Z Has data issue: false hasContentIssue false

16 - Benztropine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Cogentin

Generic?

• Yes

Class

• Antiparkinson agent, anticholinergic

Commonly Prescribed for

(FDA approved in bold)

Extrapyramidal disorders

Parkinsonism

• Acute dystonic reactions

• Idiopathic generalized dystonia

• Focal dystonias

• Dopa-responsive dystonia

How the Drug Works

• In Parkinson's disease (PD), there is a relative excess of cholinergic input. Benztropine is a synthetic anticholinergic with relatively greater CNS activity than most other anticholinergics. May also inhibit the reuptake and storage of dopamine at central dopamine receptors, prolonging dopamine action

How Long Until It Works

• PD/extrapyramidal disorders: minutes to hours

If It Works

• PD: do not abruptly discontinue or change doses of other PD treatments. Usually most effective in combination with other antiparkinsonian medications

If It Doesn't Work

• PD: generally benztropine is an adjunctive medication for common PD symptoms, such as tremor, rigidity, and drooling. Other cardinal PD symptoms, such as bradykinesia and gait difficulties, are most likely to improve with other PD treatments, such as levodopa, dopamine agonists, amantadine, or monoamine oxidase (MAO)-B inhibitors

• Acute dystonic reactions: diphenhydramine is another option, if not effective consider benzodiazepines. If possible, discontinue the agent that precipitated the extrapyramidal AE

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For bradykinesia or gait disturbances causing significant functional disturbance, levodopa is most effective. For idiopathic PD patients, especially younger patients with normal cognition and milder disability, dopamine agonists are a good first choice. Amantadine and MAO-B inhibitors may also be useful

• Depression is common in PD and may respond to low-dose SSRIs

Tests

• None

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Prevents the action of acetylcholine on muscarinic receptors

Notable AEs

• Dry mouth, tachycardia, palpitations, hypotension, disorientation, confusion, hallucinations, constipation, nausea/vomiting, dilation of colon, rash, blurred vision, diplopia, urinary retention, elevated temperature, decreased sweating, erectile dysfunction

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 58 - 61
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Benztropine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.017
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Benztropine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.017
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Benztropine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.017
Available formats
×